Article
CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.
The Journal of clinical investigation - 1 Jul 2014
Park Kang-Seo, Raffeld Mark, Moon Yong Wha, Xi Liqiang, Bianco Caterina, Pham Trung, Lee Liam C, Mitsudomi Tetsuya, Yatabe Yasushi, Okamoto Isamu, Subramaniam Deepa, Mok Tony, Rosell Rafael, Luo Ji, Salomon David S, Wang Yisong, Giaccone Giuseppe
Abstract excerpt
The majority of non-small cell lung cancer (NSCLC) patients harbor EGFR-activating mutations that can be therapeutically targeted by EGFR tyrosine kinase inhibitors (EGFR-TKI), such as erlotinib and gefitinib. Unfortunately, a subset of patients with EGFR mutations are refractory to EGFR-TKIs. Re...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
